Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $32.70 Consensus Target Price from Brokerages

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been given an average rating of “Moderate Buy” by the twelve analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $32.70.

Several equities research analysts have issued reports on AARD shares. BTIG Research began coverage on shares of Aardvark Therapeutics in a research report on Friday, November 7th. They issued a “buy” rating and a $26.00 price objective for the company. William Blair initiated coverage on Aardvark Therapeutics in a report on Friday, December 12th. They issued an “outperform” rating for the company. Royal Bank Of Canada reduced their price objective on Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 14th. Jones Trading assumed coverage on Aardvark Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $33.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on Aardvark Therapeutics in a research report on Monday, September 29th. They set a “buy” rating and a $24.00 price target on the stock.

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 7,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $14.48 per share, for a total transaction of $101,360.00. Following the acquisition, the chief executive officer directly owned 1,551,613 shares in the company, valued at approximately $22,467,356.24. The trade was a 0.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Nelson Sun bought 3,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the transaction, the chief financial officer directly owned 108,484 shares in the company, valued at approximately $1,562,169.60. This trade represents a 2.84% increase in their position. The SEC filing for this purchase provides additional information.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of large investors have recently bought and sold shares of AARD. Cantor Fitzgerald L. P. boosted its position in Aardvark Therapeutics by 26.1% during the 3rd quarter. Cantor Fitzgerald L. P. now owns 96,682 shares of the company’s stock valued at $1,285,000 after acquiring an additional 20,000 shares in the last quarter. Laurion Capital Management LP lifted its stake in shares of Aardvark Therapeutics by 6.1% during the 3rd quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock worth $13,951,000 after purchasing an additional 60,653 shares during the last quarter. Millennium Management LLC bought a new stake in Aardvark Therapeutics during the third quarter valued at about $4,248,000. Citadel Advisors LLC grew its stake in Aardvark Therapeutics by 5.9% in the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock valued at $18,073,000 after purchasing an additional 76,151 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Aardvark Therapeutics by 199.5% in the third quarter. Bank of America Corp DE now owns 23,930 shares of the company’s stock worth $318,000 after purchasing an additional 15,941 shares in the last quarter.

Aardvark Therapeutics Stock Down 4.7%

AARD stock opened at $15.08 on Friday. Aardvark Therapeutics has a twelve month low of $4.88 and a twelve month high of $19.58. The firm has a market cap of $328.29 million and a price-to-earnings ratio of -7.11. The business’s fifty day simple moving average is $12.97 and its two-hundred day simple moving average is $12.12.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.07.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.